AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27281799 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release arginine (IR-Arg) 1.5 g, 3 times/day
Number of subjects: 27
Study 27281799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release arginine (SR-Arg) 1.5 g, 3 times/day
Number of subjects: 27
Study 27281799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release arginine (SR-Arg) in HTW subjects
Number of subjects: 27
Study 27281799 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release arginine (IR-Arg) in HTW subjects
Number of subjects: 27
Study 27281799 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release arginine (SR-Arg) in CON subjects
Number of subjects: 27
Study 25749641 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 14
Study 25749641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise
Number of subjects: 14
Study 25749641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise
Number of subjects: 14
Study 25749641 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 14
Study 23860204 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 1284
Study 23860204 — intervention group
Group type: COMPARATOR
Intervention: Control (non-ESA)
Number of subjects: 1284
Study 20530222 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10 (intermediate metabolizer)
Number of subjects: 108
Study 20530222 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*4/*4 (poor metabolizer)
Number of subjects: 108
Study 20530222 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*5/*10 (intermediate metabolizer)
Number of subjects: 108
Study 20530222 — intervention group
Group type: COMPARATOR
Intervention: CYP2D6*1/*1 (extensive metabolizer)
Number of subjects: 108
Study 18795388 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exercise group (IEG; n = 30)
Number of subjects: 60
Study 18795388 — intervention group
Group type: COMPARATOR
Intervention: Delayed exercise group (DEG; n = 30)
Number of subjects: 60
Study 15367433 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen
Number of subjects: 33
Study 15367433 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning
Number of subjects: 33
Study 12438559 — intervention group
Group type: COMPARATOR
Intervention: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered intravenously (i.v.) at doses of 0.1-6 mg/kg
Number of subjects: 0
Study 12438559 — intervention group
Group type: COMPARATOR
Intervention: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered intravenously (i.v.)
Number of subjects: 0
Study 12438559 — intervention group
Group type: COMPARATOR
Intervention: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered subcutaneously (s.c.)
Number of subjects: 0
Study 10602961 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-contrast pharyngography (DCP)
Number of subjects: 151
Study 10602961 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-contrast pharyngography (DCP) and indirect laryngoscopy (IL) together
Number of subjects: 151
Study 10602961 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 151
Study 7562881 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine 20 mg twice daily for 4 weeks
Number of subjects: 0
Study 1710802 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole (antithyroid drug) for 18 months
Number of subjects: 2
Study 1710802 — intervention group
Group type: COMPARATOR
Intervention: Antithyroid drug for 6 months
Number of subjects: 2
Study 1710802 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug for 18 months
Number of subjects: 2
Study 1710802 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment clinical course
Number of subjects: 2
Study 6274563 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/kg) after 8 weeks
Number of subjects: 17
Study 6274563 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 4 weeks
Number of subjects: 17
Study 31556651 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 672
Study 28641636 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 63
Study 28641636 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 63
Study 26297084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group training
Number of subjects: 162
Study 26297084 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 162
Study 24306620 — intervention group
Group type: EXPERIMENTAL
Intervention: S SVM based method for prostate volume estimation
Number of subjects: 0
Study 24306620 — intervention group
Group type: COMPARATOR
Intervention: Prolate ellipsoid method for prostate volume estimation
Number of subjects: 0
Study 21983032 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg MDMA
Number of subjects: 10
Study 21983032 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg/kg MDMA
Number of subjects: 10
Study 21983032 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg MDMA and 1.6 mg/kg MDMA
Number of subjects: 10
Study 19647657 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during emergence from anesthesia
Number of subjects: 0
Study 19647657 — intervention group
Group type: COMPARATOR
Intervention: Parental absence during emergence from anesthesia
Number of subjects: 0
Study 17472226 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 32
Study 11573514 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (G 1, 2 Hz and 136‐184 mJ/pulse)
Number of subjects: 40
Study 11573514 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (G 2, 2 Hz and 170‐230 mJ/pulse)
Number of subjects: 40
Study 11573514 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy laser irradiation (G 2)
Number of subjects: 40
Study 9175950 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐HuEpo (480 U/kg/wk)
Number of subjects: 42
Study 9175950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1539791 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 0.25%
Number of subjects: 30
Study 1539791 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 3886278 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsam of Peru
Number of subjects: 221
Study 3886278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 3886278 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsam of Peru and Placebo
Number of subjects: 221
Study 3886278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction of balsams
Number of subjects: 221
Study 31356475 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin in lactated Ringer's solution
Number of subjects: 360
Study 31356475 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution alone
Number of subjects: 360
Study 30646345 — intervention group
Group type: EXPERIMENTAL
Intervention: Residuals cohort
Number of subjects: 1346
Study 30646345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterology care cohort
Number of subjects: 1346
Study 30646345 — intervention group
Group type: EXPERIMENTAL
Intervention: ED care cohort
Number of subjects: 1346
Study 27741005 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoidal artery ligation (DGHAL)
Number of subjects: 393
Study 27741005 — intervention group
Group type: COMPARATOR
Intervention: Circular stapled hemorrhoidopexy (SH)
Number of subjects: 393
Study 24986373 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard system (automated matched hydration)
Number of subjects: 100
Study 24986373 — intervention group
Group type: COMPARATOR
Intervention: Non-matched saline infusion (sham-controlled group)
Number of subjects: 100
Study 22932715 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire Flow Restoration Device
Number of subjects: 113
Study 22932715 — intervention group
Group type: COMPARATOR
Intervention: Merci Retrieval System
Number of subjects: 113
Study 20516538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate (1.5 ml) and hyaluronidase (1500 IU) at weekly interval for 22 weeks
Number of subjects: 100
Study 20516538 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (10 mg/ml) and hyaluronidase (1500 IU) at 15 days interval for 22 weeks
Number of subjects: 100
Study 18485551 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 18
Study 18485551 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise
Number of subjects: 18
Study 15872342 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 182
Study 15872342 — intervention group
Group type: COMPARATOR
Intervention: Stenting alone
Number of subjects: 182
Study 14685950 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight: A cognitive enhancement program for women (short-term cognitive group therapy)
Number of subjects: 19
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell add-back therapy (up to 3 doses based on risk factors for GVHD)
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: First add-back of T cells
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Second add-back of T cells
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Third add-back of T cells
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Related patients
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated patients
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall GVHD mortality
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated recipients with larger number of T cells
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated transplant
Number of subjects: 144
Study 10232737 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-free survival of patients with leukemia
Number of subjects: 144
Study 8909478 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents present with instructions on how to help their children
Number of subjects: 431
Study 8909478 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents present without instructions
Number of subjects: 431
Study 8909478 — intervention group
Group type: COMPARATOR
Intervention: Parents not present
Number of subjects: 431
Study 1859744 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 81 (SEM 32) micrograms kg‐1
Number of subjects: 40
Study 1859744 — intervention group
Group type: COMPARATOR
Intervention: Propofol 950 (400) micrograms kg‐1
Number of subjects: 40
Study 1859744 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 30414786 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tension BTB autograft
Number of subjects: 90
Study 30414786 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tension BTB autograft
Number of subjects: 90
Study 30414786 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tension HS autograft
Number of subjects: 90
Study 30414786 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tension HS autograft
Number of subjects: 90
Study 30414786 — intervention group
Group type: COMPARATOR
Intervention: HS autograft (both tension groups)
Number of subjects: 90
Study 30414786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 90
Study 27186822 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperception spinal cord stimulation at 1 kHz
Number of subjects: 22
Study 24532276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BP ≤130/85 mm Hg
Number of subjects: 91
Study 24532276 — intervention group
Group type: COMPARATOR
Intervention: Mean BP >130/85 mm Hg
Number of subjects: 91
Study 22502623 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM intervention (acupuncture, neural therapy with 1% procaine injection, cupping and bleeding, TCM herbs)
Number of subjects: 59
Study 22502623 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list, delayed treatment)
Number of subjects: 59
Study 22502623 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 59
Study 19816413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training adherers
Number of subjects: 97
Study 19816413 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training adherers
Number of subjects: 97
Study 19816413 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise group
Number of subjects: 97
Study 19816413 — intervention group
Group type: COMPARATOR
Intervention: Aerobic nonadherers
Number of subjects: 97
Study 19816413 — intervention group
Group type: COMPARATOR
Intervention: Resistance nonadherers
Number of subjects: 97
Study 18720710 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidin (TMZ) 35 mg
Number of subjects: 135
Study 18720710 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study 15802415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg-10 mg-5 mg-5 mg intravenously every 12 hours)
Number of subjects: 157
Study 15802415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 157
Study 15802415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 157
Study 15802415 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 157
Study 14674838 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically treated hypertension
Number of subjects: 40
Study 14674838 — intervention group
Group type: COMPARATOR
Intervention: Normotensive peers
Number of subjects: 40
Study 11787475 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.4 mg)
Number of subjects: 10
Study 11787475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9061418 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol
Number of subjects: 59
Study 9061418 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 59
Study 1989736 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 1 mg
Number of subjects: 92
Study 1989736 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 2 mg
Number of subjects: 92
Study 1989736 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 4 mg
Number of subjects: 92
Study 1989736 — intervention group
Group type: COMPARATOR
Intervention: Morphine 5 mg
Number of subjects: 92
Study 6410739 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 20
Study 6410739 — intervention group
Group type: COMPARATOR
Intervention: Amipaque (metrizamide)
Number of subjects: 20
Study 30849943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass media promotion of a smartphone smoking cessation app
Number of subjects: 4400000
Study 28629164 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser‐assisted cataract surgery (FLACS) using the FEMTO LDV Z8
Number of subjects: 130
Study 28629164 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 130
Study 27194530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 0.5-15mg
Number of subjects: 146
Study 27194530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 24733807 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam with tigecycline (4.5 g IV every 8 hours + 50 mg IV every 12 hours; loading dose 100 mg)
Number of subjects: 390
Study 24733807 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam monotherapy
Number of subjects: 390
Study 24733807 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam with tigecycline
Number of subjects: 390
Study 22036036 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3000 mg in divided doses
Number of subjects: 16
Study 22036036 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (0.23 mg/kg bolus, followed by 0.58 mg/kg for 30 min, then 0.29 mg/kg for 40 min)
Number of subjects: 16
Study 19769634 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sodium Phosphosoda (OSPS)
Number of subjects: 36
Study 19769634 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG)
Number of subjects: 36
Study 19769634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PEG and OSPS (PEG+OSPS)
Number of subjects: 36
Study 19769634 — intervention group
Group type: COMPARATOR
Intervention: PEG, OSPS, PEG+OSPS (all groups)
Number of subjects: 36
Study 17291843 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus exercise (n=37)
Number of subjects: 141
Study 17291843 — intervention group
Group type: EXPERIMENTAL
Intervention: NHRT plus exercise (n=35)
Number of subjects: 141
Study 17291843 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT no exercise (n=35)
Number of subjects: 141
Study 17291843 — intervention group
Group type: COMPARATOR
Intervention: Control (non-HRT no exercise, n=34)
Number of subjects: 141
Study 16321186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1.0 microg/d plus calcium carbonate 750 mg Tid
Number of subjects: 89
Study 16321186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 microg/d plus calcium carbonate 750 mg Tid
Number of subjects: 89
Study 16321186 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate 750 mg Tid
Number of subjects: 89
Study 11895272 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy School and Drugs project (intervention)
Number of subjects: 1930
Study 9866220 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodissection tonsillectomy
Number of subjects: 838
Study 9866220 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy
Number of subjects: 838
Study 7615230 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg orally once daily for 7 days (n=8)
Number of subjects: 16
Study 7615230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 16
Study 2613380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50-100 mg twice a day)
Number of subjects: 20
Study 2613380 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (40-80 mg three times a day)
Number of subjects: 20
Study 2613380 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25-0.5 mg daily)
Number of subjects: 20
Study 2613380 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 20
Study 1268490 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care by family doctor
Number of subjects: 450
Study 1268490 — intervention group
Group type: COMPARATOR
Intervention: Hospital care (initially in an intensive care unit)
Number of subjects: 450
Study 31260872 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 174
Study 31260872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 28077460 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 104
Study 28077460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 104
Study 28077460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glyburide and metformin
Number of subjects: 104
Study 28077460 — intervention group
Group type: COMPARATOR
Intervention: Glyburide and Metformin
Number of subjects: 104
Study 25541376 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable pulmonary artery pressure monitoring device (treatment group)
Number of subjects: 550
Study 25541376 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable pulmonary artery pressure monitoring device (treatment group) in COPD subgroup
Number of subjects: 550
Study 25541376 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 550
Study 22865831 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-cognition group
Number of subjects: 16
Study 22865831 — intervention group
Group type: COMPARATOR
Intervention: Motor group
Number of subjects: 16
Study 21991791 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with printed material
Number of subjects: 364
Study 19050164 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for 28 days
Number of subjects: 19
Study 19050164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16700869 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 159
Study 16700869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 15751411 — intervention group
Group type: EXPERIMENTAL
Intervention: MEOPA (nitrogen monoxide-oxygen mixture)
Number of subjects: 100
Study 15751411 — intervention group
Group type: COMPARATOR
Intervention: Control group (intrarectal xylocaine instillation)
Number of subjects: 100
Study 11343480 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical antireflux therapy
Number of subjects: 160
Study 11343480 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (fundoplication)
Number of subjects: 160
Study 11343480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Barrett esophagus
Number of subjects: 160
Study 11343480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without Barrett esophagus
Number of subjects: 160
Study 9702845 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 8 mg
Number of subjects: 9
Study 9702845 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 20 mg
Number of subjects: 9
Study 9702845 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 32 mg
Number of subjects: 9
Study 9702845 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 40 mg
Number of subjects: 9
Study 9702845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7584299 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of familiar actions after one year delay
Number of subjects: 0